ponsegromab 
GtoPdb Ligand ID: 13663
|
Synonyms: PF-06946860 | PF06946860
Compound class:
Antibody
Comment: Ponsegromab (PF-06946860) is a humanized monoclonal antibody that binds and neutralises the action of the GDF-15 cytokine. It was designed to inhibit aberrant GDF-15/GDNF family receptor alpha like (GFRAL)-mediated dysregulation of appetite in human diseases, particularly in cancer patients.
|
| No information available. |
Summary of Clinical Use  |
| Ponsegromab (PF-06946860) is a clinical candidate for the potential treatment of cancer cachexia [3]. Development for heart failure was discontinued at phase 2. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05492500 | A Study of Ponsegromab in People With Heart Failure | Phase 2 Interventional | Pfizer | ||
| NCT05546476 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 | Phase 2 Interventional | Pfizer | In this study ponsegromab promoted significant weight gain in patients with established cancer cachexia. | |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License